Full Text
Cost Utility Analysis Of Aflibercept, Ranibizumab, And Bevacizumab For The Treatment Of Neovascular Age-Related Macular Degeneration

Abstract

Authors

C.W. Lin J. Hay

Back to Volume 17, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×